Evidence map›Paper›PMID 38263522›Full record

ReviewNature protocols2024

An end-to-end workflow for nondestructive 3D pathology.

Kevin W Bishop, Lindsey A Erion Barner, Qinghua Han, Elena Baraznenok, Lydia Lan, Chetan Poudel, Gan Gao, Robert B Serafin, Sarah S L Chow, Adam K Glaser and 8 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature protocols, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Assessing the Effects of a 3-Dimensional (3D) Pathology Tissue-Processing Workflow on Downstream Molecular Analyses.Laboratory investigation; a journal of technical methods and pathology · 2026
    Article
  4. Prototype-based AI triage for 3D pathology.bioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. 3D pathology-guided microdissection.bioRxiv : the preprint server for biology · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Kevin W BishopDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.ORCID 0000-0001-8722-6464
Lindsey A Erion BarnerDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.
Qinghua HanDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.
Elena BaraznenokDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.
Lydia LanDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.
Chetan PoudelDepartment of Chemistry, University of Washington, Seattle, WA, USA.
Gan GaoDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.
Robert B SerafinDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.
Sarah S L ChowDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.ORCID 0009-0005-7519-9346
Adam K GlaserAllen Institute for Neural Dynamics, Seattle, WA, USA.
Andrew JanowczykDepartment of Biomedical Engineering, Emory University, Atlanta, GA, USA.
David BrenesDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.ORCID 0000-0003-1969-5386
Hongyi HuangDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.
Dominie MiyasatoDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.
Lawrence D TrueDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Soyoung KangDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.ORCID 0000-0002-1022-9648
Joshua C VaughanDepartment of Chemistry, University of Washington, Seattle, WA, USA.ORCID 0000-0002-6550-8935
Jonathan T C LiuDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA. jonliu@uw.edu.ORCID 0000-0001-5650-3086

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1M
KPMP Kidney Mapping and Atlas Project (KMAP)U01DK133090 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$10.4M
Computational Pathology of Proteinuric DiseasesR01DK118431 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BARISONI, LAURA MARIACHIARA, HODGIN, JEFFREY BENTON · 2018 to 2025
$3.6M
Prostate cancer risk stratification via computational 3D pathologyR01CA268207 · NCI · UNIVERSITY OF WASHINGTON · PI Jonathan T.C. Liu, Anant Madabhushi · 2022 to 2026
$3.1M
Instrumentation platform for 3D pathology with open-top light-sheet microscopyR01EB031002 · NIBIB · UNIVERSITY OF WASHINGTON · PI LIU, JONATHAN T.C. · 2021 to 2024
$1.9M
Histotools: scaling digital pathology curation tools for quality control, annotation, labeling, and dataset identificationR01LM013864 · NLM · EMORY UNIVERSITY · PI JANOWCZYK, ANDREW ROBERT · 2022 to 2025
$1.4M
RadxTools for assessing tumor treatment response on imagingU01CA248226 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI TIWARI, PALLAVI, VISWANATH, SATISH EASWAR · 2020 to 2022
$1.4M
HistoTools: A suite of digital pathology tools for quality control, annotation and dataset identificationU01CA239055 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JANOWCZYK, ANDREW ROBERT, MADABHUSHI, ANANT · 2019 to 2022
$1.0M
Light-sheet micro-aspiration microscopy for the isolation and analysis of rare tumor cells from intact clinical specimensR00CA240681 · NCI · ALLEN INSTITUTE · PI GLASER, ADAM K · 2021 to 2023
$745k
NCI NIH HHS P50 CA097186NCI NIH HHS R00 CA240681NCI NIH HHS R01 CA268207NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NIBIB NIH HHS R01 EB031002NIDDK NIH HHS R01 DK118431NIDDK NIH HHS U01 DK133090NLM NIH HHS R01 LM013864Prostate Cancer UK MA-ETNA19-005
6 · The paper itself

Abstract

Recent advances in 3D pathology offer the ability to image orders of magnitude more tissue than conventional pathology methods while also providing a volumetric context that is not achievable with 2D tissue sections, and all without requiring destructive tissue sectioning. Generating high-quality 3D pathology datasets on a consistent basis, however, is not trivial and requires careful attention to a series of details during tissue preparation, imaging and initial data processing, as well as iterative optimization of the entire process. Here, we provide an end-to-end procedure covering all aspects of a 3D pathology workflow (using light-sheet microscopy as an illustrative imaging platform) with sufficient detail to perform well-controlled preclinical and clinical studies. Although 3D pathology is compatible with diverse staining protocols and computationally generated color palettes for visual analysis, this protocol focuses on the use of a fluorescent analog of hematoxylin and eosin, which remains the most common stain used for gold-standard pathological reports. We present our guidelines for a broad range of end users (e.g., biologists, clinical researchers and engineers) in a simple format. The end-to-end workflow requires 3-6 d to complete, bearing in mind that data analysis may take longer.

Indexed as

Imaging, Three-DimensionalMicroscopyColoring AgentsStaining and LabelingWorkflowColoring Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.